This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zugck, C. Articles by Haass, M. Search for Related Content PubMed PubMed Citation Articles by Zugck, C. Articles by Haass, M.

CLINICAL STUDY: HEART FAILURE

Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure

^* Department of Cardiology, University of Heidelberg, Heidelberg, Germany

Manuscript received August 13, 2001; revised manuscript received February 20, 2002, accepted February 25, 2002.

^* Reprint requests and correspondence: Dr. Markus Haass, Department of Cardiology, University of Heidelberg, Bergheimerstrasse 58, D-69115 Heidelberg, Germany.
markus_haass{at}med.uni-heidelberg.de

OBJECTIVES: This prospective study tested the impact of beta-blocker treatment on currently used risk predictors in congestive heart failure (CHF).

BACKGROUND: Given the survival benefit obtained by beta-blockade, risk stratification by factors established in the "pre–beta-blocker era" may be questioned.

METHODS: The study included 408 patients who had CHF with left ventricular ejection fraction (LVEF) <45%, all treated with an angiotensin-converting enzyme inhibitor or angiotensin type 1 receptor antagonist, who were classified into those receiving a beta-blocker (n = 165) and those who were not (n = 243). In all patients, LVEF, peak oxygen consumption (peakVO₂), plasma norepinephrine (NE) and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were determined.

RESULTS: Although the New York Heart Association functional class (2.2 ± 0.7 vs. 2.3 ± 0.7), peakVO₂ (14.4 ± 5.2 ml/min per kg vs. 14.4 ± 5.5 ml/min per kg) and NT-proBNP (337 ± 360 pmol/l vs. 434 ± 538 pmol/l) were similar in the groups with and without beta-blocker treatment, the group with beta-blocker treatment had a lower heart rate (68 ± 30 beats/min vs. 76 ± 30 beats/min), lower NE (1.7 ± 1.2 nmol/l vs. 2.5 ± 2.2 nmol/l) and higher LVEF (24 ± 10% vs. 21 ± 9%; all p < 0.05). Within one year, 34% of patients without beta-blocker treatment, but only 16% of those with beta-blocker treatment (p < 0.001), reached the combined end point, defined as hospital admission due to worsening CHF and/or cardiac death. A beneficial effect of beta-blocker treatment was most obvious in the advanced stages of CHF, because the end-point rates were markedly lower (all p < 0.05) in the group with beta-blocker treatment versus the group without it, as characterized by peakVO₂ <10 ml/min per kg (26% vs. 64%), LVEF 20% (25% vs. 45%), NE >2.24 nmol/l (18% vs. 40%) and NT-proBNP >364 pmol/l (27% vs. 45%), although patients with beta-blocker treatment received only 37 ± 21% of the maximal recommended beta-blocker dosages.

CONCLUSIONS: The prognostic value of variables used for risk stratification of patients with CHF is markedly influenced by beta-blocker treatment. Therefore, in the beta-blocker era, a re-evaluation of the selection criteria for heart transplantation is warranted.

Abbreviations and Acronyms   ACE   angiotensin-converting enzyme   AT1   angiotensin type 1 receptor   CHF   congestive heart failure   LVEF   left ventricular ejection fraction   NE   norepinephrine   NT-proBNP   N-terminal pro-brain natriuretic peptide   NYHA   New York Heart Association   PeakVO2   peak oxygen consumption

This article has been cited by other articles:

				U. Corra, A. Mezzani, A. Giordano, E. Bosimini, and P. Giannuzzi Exercise haemodynamic variables rather than ventilatory efficiency indexes contribute to risk assessment in chronic heart failure patients treated with carvedilol Eur. Heart J., April 30, 2009; (2009) ehp138v1. [Abstract] [Full Text] [PDF]

				N. M. Albert Improving Medication Adherence in Chronic Cardiovascular Disease Crit. Care Nurse, October 1, 2008; 28(5): 54 - 64. [Full Text] [PDF]

				M. Rosenberg, C. Zugck, M. Nelles, C. Juenger, D. Frank, A. Remppis, E. Giannitsis, H. A. Katus, and N. Frey Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure Circ Heart Fail, May 1, 2008; 1(1): 43 - 49. [Abstract] [Full Text] [PDF]

				L. Ingle Prognostic value and diagnostic potential of cardiopulmonary exercise testing in patients with chronic heart failure Eur J Heart Fail, February 1, 2008; 10(2): 112 - 118. [Abstract] [Full Text] [PDF]

				P. E. F. Daubeney, A. W. Nugent, P. Chondros, J. B. Carlin, S. D. Colan, M. Cheung, A. M. Davis, C.W. Chow, R. G. Weintraub, and on behalf of the National Australian Childhood Car Clinical Features and Outcomes of Childhood Dilated Cardiomyopathy: Results From a National Population-Based Study Circulation, December 12, 2006; 114(24): 2671 - 2678. [Abstract] [Full Text] [PDF]

				R. V. Milani, C. J. Lavie, M. R. Mehra, and H. O. Ventura Understanding the Basics of Cardiopulmonary Exercise Testing Mayo Clin. Proc., December 1, 2006; 81(12): 1603 - 1611. [Abstract] [Full Text] [PDF]

				A. Passantino, R. Lagioia, F. Mastropasqua, and D. Scrutinio Short-Term Change in Distance Walked in 6 Min Is an Indicator of Outcome in Patients With Chronic Heart Failure in Clinical Practice J. Am. Coll. Cardiol., July 4, 2006; 48(1): 99 - 105. [Abstract] [Full Text] [PDF]

				M. E. Davis, A. M. Richards, M. G. Nicholls, T. G. Yandle, C. M. Frampton, and R. W. Troughton Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure Circulation, February 21, 2006; 113(7): 977 - 985. [Abstract] [Full Text] [PDF]

				A. Cohen-Solal, F. Rouzet, A. Berdeaux, D. Le Guludec, E. Abergel, A. Syrota, and P. Merlet Effects of Carvedilol on Myocardial Sympathetic Innervation in Patients with Chronic Heart Failure J. Nucl. Med., November 1, 2005; 46(11): 1796 - 1803. [Abstract] [Full Text] [PDF]

				J. O. O'Neill, J. B. Young, C. E. Pothier, and M. S. Lauer Peak Oxygen Consumption as a Predictor of Death in Patients With Heart Failure Receiving {beta}-Blockers Circulation, May 10, 2005; 111(18): 2313 - 2318. [Abstract] [Full Text] [PDF]

				J. A Doust, E. Pietrzak, A. Dobson, and P. Glasziou How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ, March 19, 2005; 330(7492): 625. [Abstract] [Full Text] [PDF]

				R. Schnabel, H. J. Rupprecht, K. J. Lackner, E. Lubos, C. Bickel, J. Meyer, T. Munzel, F. Cambien, L. Tiret, S. Blankenberg, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study Eur. Heart J., February 1, 2005; 26(3): 241 - 249. [Abstract] [Full Text] [PDF]

				U. Corra, A. Mezzani, E. Bosimini, and P. Giannuzzi Cardiopulmonary Exercise Testing and Prognosis in Chronic Heart Failure*: A Prognosticating Algorithm for the Individual Patient Chest, September 1, 2004; 126(3): 942 - 950. [Abstract] [Full Text] [PDF]

				R. V. Milani, C. J. Lavie, and M. R. Mehra Cardiopulmonary Exercise Testing: How Do We Differentiate the Cause of Dyspnea? Circulation, July 27, 2004; 110(4): e27 - e31. [Full Text] [PDF]

				P. Tandon, F. A. McAlister, R. T. Tsuyuki, M. Hervas-Malo, R. Dupuit, J. Ezekowitz, B. Cujec, and P. W. Armstrong The Use of {beta}-Blockers in a Tertiary Care Heart Failure Clinic: Dosing, Tolerance, and Outcomes Arch Intern Med, April 12, 2004; 164(7): 769 - 774. [Abstract] [Full Text] [PDF]

				J. Butler, G. Khadim, K. M. Paul, S. F. Davis, M. W. Kronenberg, D. B. Chomsky, R. N. Pierson III, and J. R. Wilson Selection of patients for heart transplantationin the current era of heart failure therapy J. Am. Coll. Cardiol., March 3, 2004; 43(5): 787 - 793. [Abstract] [Full Text] [PDF]

				S. de Denus, C. Pharand, and D. R. Williamson Brain Natriuretic Peptide in the Management of Heart Failure: The Versatile Neurohormone Chest, February 1, 2004; 125(2): 652 - 668. [Abstract] [Full Text] [PDF]

				M.R Cowie, P Jourdain, A Maisel, U Dahlstrom, F Follath, R Isnard, A Luchner, T McDonagh, J Mair, M Nieminen, et al. Clinical applications of B-type natriuretic peptide (BNP) testing Eur. Heart J., October 1, 2003; 24(19): 1710 - 1718. [Abstract] [Full Text] [PDF]

				R.S. Gardner, F. Ozalp, A.J. Murday, S.D. Robb, and T.A. McDonagh N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure Eur. Heart J., October 1, 2003; 24(19): 1735 - 1743. [Abstract] [Full Text] [PDF]

				H. Rickli, W. Kiowski, M. Brehm, D. Weilenmann, C. Schalcher, A. Bernheim, E. Oechslin, and H. P. Brunner-La Rocca Combining low-intensity and maximal exercise test results improves prognostic prediction in chronic heart failure J. Am. Coll. Cardiol., July 2, 2003; 42(1): 116 - 122. [Abstract] [Full Text] [PDF]

				V. Bittner Exercise testing in heart failure: Maximal, submaximal, or both? J. Am. Coll. Cardiol., July 2, 2003; 42(1): 123 - 125. [Full Text] [PDF]

				M. T. La Rovere, G. D. Pinna, R. Maestri, A. Mortara, S. Capomolla, O. Febo, R. Ferrari, M. Franchini, M. Gnemmi, C. Opasich, et al. Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients Circulation, February 4, 2003; 107(4): 565 - 570. [Abstract] [Full Text] [PDF]